**Supplementary Table S3. HER2-enriched molecular subtype: patients’ characteristics according to *PIK3CA* gene status.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Characteristics** |  |  | ***PIK3CA***  **mutated** | ***PIK3CA* wild-type** | **TOT HER2-enriched** | ***P* value** |
|  |  |  | ***N* (%)** | ***N* (%)** | ***N* (%)** |  |
| Total |  |  | 49 (21%) | 183 (79%) | 232 (100%) | - |
| Age (years) |  |  |  |  |  |  |
|  | <60 |  | 30 (61) | 123 (67) | 153 (66) |  |
|  | ≥60 |  | 19 (39) | 60 (33) | 79 (34) | 0.432 |
|  | Median (Q1-Q3) |  | 57 (49-64) | 55 (47-63) | 55 (48-64) | 0.441 |
| Menopausal status |  |  |  |  |  |  |
| Premenopausal |  | 18 (37) | 66 (36) | 84 (36) |  |
| Postmenopausal |  | 431 (63) | 117 (64) | 148 (64) | 0.931 |
| AJCC Stage |  |  |  |  |  |  |
|  | I |  | 13 (27) | 61 (33) | 74 (32) |  |
|  | II |  | 29 (59) | 87 (48) | 116 (50) |  |
|  | III |  | 7 (14) | 34 (19) | 41 (18) | 0.367 |
| N stage |  |  |  |  |  |  |
|  | N0  N1-N2  N3 |  | 25 (51)  17 (35)  7 (14) | 92 (50)  54 (30)  37 (20) | 117 (50)  71 (31)  44 (19) | 0.588 |
| Hormone receptors |  |  |  |  |  |  |
|  | Negative |  | 14 (29) | 74 (40) | 88 (38) |  |
|  | Positive |  | 35 (71) | 109 (60) | 144 (62) | 0.128 |
| Histological grade |  |  |  |  |  |  |
|  | Grade 1- 2 |  | 10 (21) | 40 (22) | 50 (22) |  |
|  | Grade 3 |  | 37 (79) | 141 (78) | 178 (78) | 0.903 |
| TILs | Median (Q1-Q3) |  | 8 (2-30) | 5 (1-20) | 5 (1-20) | 0.164 |

Abbreviations: TILs, tumor infiltrating lymphocytes; AJCC, American Joint Committee on Cancer.